Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis
- Conditions
- SarcoidosisCardiomyopathies
- Registration Number
- NCT03561025
- Lead Sponsor
- St. Olavs Hospital
- Brief Summary
The aim of the study is to find better and more specific non-invasive methods to diagnose and stage cardiac sarcoidosis with the use of advanced imaging modalities, simultaneous 3T MRI and PET. Cardiac sarcoidosis is a disease of possibly fatal outcome in young people. The use of a combined PET/MRI system with 18F-FDG and a new inflammation-tracer (18F-GE180) can become a future game changer.
Sarcoid induced focal inflammation in myocardium should show high 18F-GE180 uptake. 18F-GE180 PET scans will give reliable data about inflammatory sarcoidosis activity in the myocardium. 18F-GE180 PET is expected to improve diagnostic accuracy compared to 18F-FDG-PET and/or contrast enhanced MRI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- Heart department: Suspicion of myocardial sarcoidosis after contrast enhanced cardiac MRI
- Lung department: Clinically verified lung and/or mediastinal sarcoidosis
- Known malignancies
- Treatment for sarcoidosis started
- Severe arrhythmia
- Patients with pacemakers or defibrillator
- Claustrophobia
- Known alcohol or drug abuse
- Kidney failure (eGFR < 30)
- Weight > 120 kg
- Diabetes Mellitus type I and II
- Patients that take immunosuppressive or immunomodulatory medication for any reason
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method diagnostic accuracy of a combined 18F-FDG and 18F-GE-180 PET/MRI examination for diagnosing cardiac sarcoidosis One day after the test
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
St Olav University Hospital, Dept Radiology and Nuclear Medicine
🇳🇴Trondheim, Norway
St Olav University Hospital, Dept Radiology and Nuclear Medicine🇳🇴Trondheim, Norway